市场调查报告书
商品编码
1541643
2024-2032 年按营养素类型(碳水化合物、脂质乳液、单剂量氨基酸溶液、微量元素、维生素和矿物质)、最终用户(医院、诊所等)和地区分類的肠外营养市场报告Parenteral Nutrition Market Report by Nutrient Type (Carbohydrates, Lipid Emulsion, Single Dose Amino Acid Solution, Trace Elements, Vitamins and Minerals), End User (Hospitals, Clinics, and Others), and Region 2024-2032 |
IMARC Group年全球肠外营养市场规模达72亿美元。
肠外营养 (PN) 或静脉餵食提供液体营养物质,如脂肪、蛋白质、维生素、矿物质、碳水化合物和电解质。它是专门营养治疗的一部分,为无法利用胃肠道的患者提供营养支持。它有助于预防营养不良并保持能量、水分和力量水平。因此,它被广泛用于患有癌症、克隆氏症、短肠症候群、缺血性肠病和肠功能异常的患者。
营养不良盛行率上升、出生率上升和早产增加是推动全球营养需求的主要因素。此外,患有气喘、白血病、结核病、支气管炎、水痘和贫血等儿科疾病的人数显着增加。再加上相对更容易患慢性病的老年人口不断增加,也对 PN 产品的需求产生了正面影响。此外,速食消费的增长导致高血压、糖尿病、肥胖和其他代谢紊乱等非传染性疾病的发生率不断增加。再加上肝功能不全、肾功能不全和蛋白质能量营养不良的发生率不断上升,富含羊酸和肠外产品的消费量也增加。 PN 的显着改进进一步推动了市场,例如脂肪乳剂优化和间接量热法的利用。其他一些因素,例如多个国家的管理机构和私人实体对医疗保健行业整体发展的支出增加以及医疗保健行业越来越多地采用 PN 产品,预计将加强全球市场的成长。
The global parenteral nutrition market size reached US$ 7.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.2 Billion by 2032, exhibiting a growth rate (CAGR) of 5.9% during 2024-2032.
Parenteral nutrition (PN), or intravenous feeding, offers liquid nutrients like fats, proteins, vitamins, minerals, carbohydrates, and electrolytes. It is a part of specialized nutritional therapy that providing nutritional support to patients who are unable to utilize their gastrointestinal tract. It aids in preventing malnutrition and maintaining energy, hydration, and strength levels. As a result, it is widely used among patients who are suffering from cancer, Crohn's disease, short bowel syndrome, ischemic bowel disease, and abnormal bowel function.
The rising prevalence of malnutrition, growing natality rate, and increasing premature births are among the primary factors catalyzing the demand for PN around the world. Moreover, there is a considerable rise in the number of individuals experiencing pediatric disorders, such as asthma, leukemia, tuberculosis, bronchitis, chickenpox, and anemia. This, along with the rising geriatric population, which is relatively more prone to chronic diseases, is also influencing the demand for PN products positively. Furthermore, the growing consumption of fast food has resulted in the growing instances of non-communicable diseases like hypertension, diabetes, obesity, and other metabolic disorders. This, in confluence with the rising incidences of hepatic insufficiency, renal insufficiency and protein-energy malnutrition, is increasing the consumption of amnio acid-rich and parenteral products. The market is further driven by significant improvements in the PN, such as lipid emulsions optimizations and utilization of indirect calorimetry. Some of the other factors, such as increasing expenditure on the overall development of the healthcare sector by the governing agencies and private entities of several countries and rising adoption of PN products by the healthcare sector, are anticipated to strengthen the market growth across the globe.
IMARC Group provides an analysis of the key trends in each sub-segment of the global parenteral nutrition market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on nutrient type and end user.
Carbohydrates
Lipid Emulsion
Single Dose Amino Acid Solution
Trace Elements
Vitamins and Minerals
Hospitals
Clinics
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aculife Healthcare Private Limited, B. Braun Melsungen AG, Baxter International Inc., Fresenius SE & Co. KGaA, Grifols S.A., Otsuka Pharmaceutical Factory Inc., Pfizer Inc. and Servona GmbH.